| Lawrence Lamb |
INAB |
Employee Stock Option (right to buy) |
Award |
|
|
|
72,000 |
72,000 |
04 Feb 2026 |
Direct |
| Patrick McCall |
INAB |
Employee Stock Option (right to buy) |
Award |
|
|
|
75,000 |
75,000 |
04 Feb 2026 |
Direct |
| Kate Rochlin |
INAB |
Employee Stock Option (right to buy) |
Award |
|
|
|
80,000 |
80,000 |
04 Feb 2026 |
Direct |
| William Tai-Wei Ho |
INAB |
Employee Stock Option (right to buy) |
Award |
|
|
|
206,000 |
206,000 |
04 Feb 2026 |
Direct |
| Kate Rochlin |
INAB |
Common Stock |
Award |
394.3% |
|
|
7,247 |
9,085 |
22 Dec 2025 |
Direct |
| Patrick McCall |
INAB |
Common Stock |
Award |
324.2% |
|
|
7,247 |
9,482 |
22 Dec 2025 |
Direct |
| William Tai-Wei Ho |
INAB |
Common Stock |
Award |
42.7% |
|
|
36,232 |
121,168 |
22 Dec 2025 |
Direct |
| Alan S. Roemer |
INAB |
Common Stock |
Award |
272.8% |
|
|
36,232 |
49,514 |
22 Dec 2025 |
Direct |
| Peter C. Brandt |
INAB |
Common Stock |
Award |
319% |
|
|
72,464 |
95,181 |
22 Dec 2025 |
Direct |
| Emily Fairbairn |
INAB |
Common Stock |
Award |
|
|
|
724,637 |
724,637 |
22 Dec 2025 |
See footnote |
| Luba Greenwood |
INAB |
Stock Option (right to buy) |
Award |
|
|
|
63,150 |
63,150 |
08 May 2025 |
Direct |
| Jeremy R. Graff |
INAB |
Stock Option (right to buy) |
Award |
|
|
|
63,150 |
63,150 |
08 May 2025 |
Direct |
| Emily Fairbairn |
INAB |
Stock Option (right to buy) |
Award |
|
|
|
63,150 |
63,150 |
08 May 2025 |
Direct |
| Corinne Epperly |
INAB |
Stock Option (right to buy) |
Award |
|
|
|
63,150 |
63,150 |
08 May 2025 |
Direct |
| Peter C. Brandt |
INAB |
Stock Option (right to buy) |
Award |
|
|
|
63,150 |
63,150 |
08 May 2025 |
Direct |
| Alan S. Roemer |
INAB |
Stock Option (right to buy) |
Award |
|
|
|
63,150 |
63,150 |
08 May 2025 |
Direct |
| Aaron G.l. Fletcher |
INAB |
Series B Warrant |
Other |
-100% |
|
|
-574,241 |
0 |
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| Aaron G.l. Fletcher |
INAB |
Series A Warrant |
Other |
-100% |
|
|
-574,241 |
0 |
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| Aaron G.l. Fletcher |
INAB |
Pre-Funded Warrants |
Purchase |
89.5% |
|
|
1,148,482 |
2,431,763 |
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| Leslie W. Kreis |
INAB |
Series B Warrant |
Other |
-100% |
|
|
-574,241 |
0 |
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| Leslie W. Kreis |
INAB |
Series A Warrant |
Other |
-100% |
|
|
-574,241 |
0 |
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| Leslie W. Kreis |
INAB |
Pre-Funded Warrants |
Purchase |
89.5% |
|
|
1,148,482 |
2,431,763 |
02 May 2025 |
By Bios Clinical Opportunity Fund, LP |
| William Tai-Wei Ho |
INAB |
Pre-Funded Warrant (right to buy) |
Award |
|
|
|
81,967 |
81,967 |
01 May 2025 |
Direct |
| William Tai-Wei Ho |
INAB |
Series A Warrants (right to buy) |
Disposed to Issuer |
-100% |
|
|
-81,967 |
0 |
01 May 2025 |
Direct |
| Kate Rochlin |
INAB |
Common Stock |
Options Exercise |
28.7% |
|
|
12,295 |
55,169 |
30 Apr 2025 |
Direct |
| Kate Rochlin |
INAB |
Series A Warrants (right to buy) |
Options Exercise |
-100% |
|
|
-12,295 |
0 |
30 Apr 2025 |
Direct |
| Patrick McCall |
INAB |
Common Stock |
Options Exercise |
28.8% |
|
|
15,000 |
67,071 |
30 Apr 2025 |
Direct |
| Patrick McCall |
INAB |
Series A Warrants (right to buy) |
Options Exercise |
-100% |
|
|
-15,000 |
0 |
30 Apr 2025 |
Direct |
| Alan S. Roemer |
INAB |
Common Stock |
Options Exercise |
39.8% |
|
|
113,459 |
398,489 |
30 Apr 2025 |
Direct |
| Alan S. Roemer |
INAB |
Series B Warrants (right to buy) |
Options Exercise |
-100% |
|
|
-11,000 |
0 |
30 Apr 2025 |
Direct |
| Alan S. Roemer |
INAB |
Series A Warrants (right to buy) |
Options Exercise |
-100% |
|
|
-102,459 |
0 |
30 Apr 2025 |
Direct |
| Peter C. Brandt |
INAB |
Common Stock |
Options Exercise |
31.7% |
|
|
163,934 |
681,538 |
30 Apr 2025 |
Direct |
| Peter C. Brandt |
INAB |
Series B Warrants (right to buy) |
Options Exercise |
-100% |
|
|
-81,967 |
0 |
30 Apr 2025 |
Direct |
| Peter C. Brandt |
INAB |
Series A Warrants (right to buy) |
Options Exercise |
-100% |
|
|
-81,967 |
0 |
30 Apr 2025 |
Direct |
| Lawrence Lamb |
INAB |
Series B Warrants (right to buy) |
Award |
|
|
|
1,639 |
1,639 |
27 Apr 2025 |
Direct |
| Lawrence Lamb |
INAB |
Series B Warrants (right to buy) |
Disposed to Issuer |
-100% |
|
|
-1,639 |
0 |
27 Apr 2025 |
Direct |
| Jeremy R. Graff |
INAB |
Series B Warrants (right to buy) |
Award |
|
|
|
2,049 |
2,049 |
27 Apr 2025 |
Direct |
| Jeremy R. Graff |
INAB |
Series B Warrants (right to buy) |
Disposed to Issuer |
-100% |
|
|
-2,049 |
0 |
27 Apr 2025 |
Direct |
| Corinne Epperly |
INAB |
Series B Warrants (right to buy) |
Award |
|
|
|
81,967 |
81,967 |
27 Apr 2025 |
Direct |
| Corinne Epperly |
INAB |
Series B Warrants (right to buy) |
Disposed to Issuer |
-100% |
|
|
-81,967 |
0 |
27 Apr 2025 |
Direct |
| William Tai-Wei Ho |
INAB |
Series B Warrants (right to buy) |
Award |
|
|
|
81,967 |
81,967 |
27 Apr 2025 |
Direct |
| William Tai-Wei Ho |
INAB |
Series B Warrants (right to buy) |
Disposed to Issuer |
-100% |
|
|
-81,967 |
0 |
27 Apr 2025 |
Direct |
| Kate Rochlin |
INAB |
Series B Warrants (right to buy) |
Award |
|
|
|
12,295 |
12,295 |
27 Apr 2025 |
Direct |
| Kate Rochlin |
INAB |
Series B Warrants (right to buy) |
Disposed to Issuer |
-100% |
|
|
-12,295 |
0 |
27 Apr 2025 |
Direct |
| Kate Rochlin |
INAB |
Series A Warrants (right to buy) |
Award |
|
|
|
12,295 |
12,295 |
27 Apr 2025 |
Direct |
| Kate Rochlin |
INAB |
Series A Warrants (right to buy) |
Disposed to Issuer |
-100% |
|
|
-12,295 |
0 |
27 Apr 2025 |
Direct |
| Patrick McCall |
INAB |
Series B Warrants (right to buy) |
Award |
|
|
|
20,492 |
20,492 |
27 Apr 2025 |
Direct |
| Patrick McCall |
INAB |
Series B Warrants (right to buy) |
Disposed to Issuer |
-100% |
|
|
-20,492 |
0 |
27 Apr 2025 |
Direct |
| Patrick McCall |
INAB |
Series A Warrants (right to buy) |
Award |
|
|
|
15,000 |
15,000 |
27 Apr 2025 |
Direct |
| Patrick McCall |
INAB |
Series A Warrants (right to buy) |
Disposed to Issuer |
-73.2% |
|
|
-15,000 |
5,492 |
27 Apr 2025 |
Direct |